Literature DB >> 35881334

Collection and Cryopreservation of Plasmodium falciparum Clinical Isolates in the Field.

Frederica Dedo Partey1, Augustina Frimpong1, Michael Fokuo Ofori2.   

Abstract

P. falciparum causes the most severe form of malaria in younger children and pregnant women. In vitro culture systems allow researchers to understand parasite biology, elucidate mechanism of host immunity and test efficacy of antimalarial agents or vaccines in preclinical studies. Most laboratory-adapted parasite strains predate the emergence of artemisinin-based drug combinations and mainly originate from Asia or Europe. To fully understand the biochemical and phenotypic characteristics of parasites, it is imperative that researchers are able to culture parasites circulating in an area to unravel any geographical differences at the population level. Ex vivo culturing of clinical isolates can be challenging when collecting samples in the field and requires technical expertise and equipment. To overcome this challenge, clinical isolates are cryopreserved in the field and transported to a laboratory for in vitro studies. In this protocol, we describe different methods of cryopreserving P. falciparum isolates in the field and thawing them for subsequent in vitro culture.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Clinical isolate; Cryopreservation; Field isolate; Glycerolyte; P. falciparum; Snap freezing; Thawing parasites

Mesh:

Substances:

Year:  2022        PMID: 35881334     DOI: 10.1007/978-1-0716-2189-9_2

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  16 in total

1.  RTS,S malaria vaccine pilots in three African countries.

Authors:  Paul Adepoju
Journal:  Lancet       Date:  2019-04-27       Impact factor: 79.321

2.  Cloning of naturally occurring mixed infections of malaria parasites.

Authors:  V Rosario
Journal:  Science       Date:  1981-05-29       Impact factor: 47.728

3.  Plasmodium falciparum: induction of resistance to mefloquine in cloned strains by continuous drug exposure in vitro.

Authors:  A M Oduola; W K Milhous; N F Weatherly; J H Bowdre; R E Desjardins
Journal:  Exp Parasitol       Date:  1988-12       Impact factor: 2.011

4.  Human malaria parasites in continuous culture.

Authors:  W Trager; J B Jensen
Journal:  Science       Date:  1976-08-20       Impact factor: 47.728

5.  Genetic analysis of the human malaria parasite Plasmodium falciparum.

Authors:  D Walliker; I A Quakyi; T E Wellems; T F McCutchan; A Szarfman; W T London; L M Corcoran; T R Burkot; R Carter
Journal:  Science       Date:  1987-06-26       Impact factor: 47.728

6.  Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children.

Authors:  Ally Olotu; Gregory Fegan; Juliana Wambua; George Nyangweso; Amanda Leach; Marc Lievens; David C Kaslow; Patricia Njuguna; Kevin Marsh; Philip Bejon
Journal:  N Engl J Med       Date:  2016-06-30       Impact factor: 91.245

7.  Advances in malaria vaccine development: report from the 2017 malaria vaccine symposium.

Authors:  Camila Henriques Coelho; Justin Yai Alamou Doritchamou; Irfan Zaidi; Patrick E Duffy
Journal:  NPJ Vaccines       Date:  2017-11-30       Impact factor: 7.344

8.  A Study of Monkey-Malaria, and Its Experimental Transmission to Man.

Authors:  R Knowles; B M Das Gupta
Journal:  Ind Med Gaz       Date:  1932-06

9.  Schizont transcriptome variation among clinical isolates and laboratory-adapted clones of the malaria parasite Plasmodium falciparum.

Authors:  Sarah J Tarr; Ofelia Díaz-Ingelmo; Lindsay B Stewart; Suzanne E Hocking; Lee Murray; Craig W Duffy; Thomas D Otto; Lia Chappell; Julian C Rayner; Gordon A Awandare; David J Conway
Journal:  BMC Genomics       Date:  2018-12-10       Impact factor: 3.969

Review 10.  Recent advances in recombinant protein-based malaria vaccines.

Authors:  Simon J Draper; Evelina Angov; Toshihiro Horii; Louis H Miller; Prakash Srinivasan; Michael Theisen; Sumi Biswas
Journal:  Vaccine       Date:  2015-10-11       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.